last week the company included this paragraph in their announcement:
"The potential of MSCs for treating the consequences of COVID-19 is underpinned by very recent clinical results in
China, suggesting that MSCs may protect against serious outcomes of the infection, particularly pneumonia. Critically
ill COVID-19 patients in China favourably responded to treatment with MSCs in a clinical study"
This text was echoed in todays Financial review, in an interview seemingly with Martin Rogers of KTM Ventures, who has been associated with the Cynata in the past.
The article in the AFR said :
"The company is developing a stem cell treatment that is already being used to treat patients in China".
I think we need an explanation here. Either the AFR have misreported or the company have not represented the situation sufficiently in the announcement last week.
Are Cynata actively deploying or testing Cymerus in China for Covid-19, or not?
Please explain
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.005(2.00%) |
Mkt cap ! $45.80M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 25.5¢ | 25.5¢ | $313 | 1.229K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 22209 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 36715 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |